Diagnosis of attention deficit hyperactivity disorder
This invention features methods and compositions useful for the treatment and diagnosis of attentional disorders including attention deficit hyperactivity disorder (ADHD). Also disclosed are methods for identifying compounds useful for such therapy.
1. A method for diagnosing a subject as having an increased likelihood of developing attention deficit hyperactivity disorder (ADHD), comprising the steps of:
(a) determining the nucleotide base in the human norepinephrine transporter (hNET) gene promoter corresponding to position 954 of SEQ ID NO: 2; and
(b) diagnosing the subject as having an increased likelihood of developing ADHD when said nucleotide is thymine.
2. The method of claim 1 , wherein said method comprises at least one method selected from the group consisting of restriction fragment length polymorphism analysis, polymerase chain reaction, nucleotide sequencing, nucleotide sequencing by primer extension, and allele-specific polymerase chain reaction.
3. The method of claim 2 , wherein said method comprises restriction fragment length polymorphism analysis.
4. The method of claim 3 , wherein said restriction fragment length polymorphism analysis is performed using endonuclease BsrI.
5. A method for confirming a diagnosis of attention deficit hyperactivity disorder (ADHD) in a subject, comprising the steps of:
(a) determining the nucleotide base in the human norepinephrine transporter (hNET) gene promoter corresponding to position 954 of SEQ ID NO: 2; and
(b) confirming the diagnosis of ADHD in the subject when said nucleotide is thymine.
6. The method of claim 5 , wherein said method comprises at least one method selected from the group consisting of restriction fragment length polymorphism analysis, polymerase chain reaction, nucleotide sequencing, nucleotide sequencing by primer extension, and allele-specific polymerase chain reaction.
7. The method of claim 6 , wherein said method comprises restriction fragment length polymorphism analysis.
8. The method of claim 7 , wherein said restriction fragment length polymorphism analysis is performed using endonuclease BsrI.